“The AstraZeneca COVID-19 vaccine, including the Covishield vaccine, continues to have positive benefits and risks, with tremendous potential to prevent infection and reduce mortality worldwide,” the press release said.
The WHO committee added that the data analyzed did not indicate an increased risk of worsening blood clotting, deep vein thrombosis or pulmonary embolism after drug administration.
According to available data, these conditions can occur naturally or as a result of COVID-19 disease and their direct relationship with vaccination has not been proven.
At the same time, WHO called on to educate medical staff and those wishing to be vaccinated about the possible side effects of all vaccines from COVID-19.
On March 8, the expert committee on the safety of drugs of the European Medicines Agency, during an assessment of information on complications in those vaccinated with the AstraZeneca vaccine against coronavirus, did not find an unambiguous connection between cases of thrombosis and the use of the drug.